Heart failure treatment, ARNI therapy, has been studied and researched previously and it has demonstrated the effectiveness in reducing death rate in patients with heart failure.

Heart failure treatment using ARNI therapy

With ARNI therapy, patient's protective hormonal system is enhanced - enabling it to slow down the increase of overactive harmful hormones.

The implementation of ARNI therapy has comprehensively helped many patients diagnosed with heart failure and this time, UCLA wants to find out the exact number of death rate that can be reduced when using the heart failure treatment.

The quantitative study used the published sources to analyze the expected mortality benefits using the heart failure treatment. The elements of this study include patients of ARNI therapy, the amount of patients diagnosed with heart failure in the US, and reduced ejection fraction, and how many of them need to be treated with this heart failure treatment to prevent death.

Almost 3 million Americans diagnosed with heart failure

84 percent of the amount can potentially be treated using ARNI therapy. Thus, if the heart failure treatment is applied in a comprehensive way, the amount of death rate reduced each year will be estimated around 28,484 deaths, MPR reported.

Researchers suggest optimizing the ARNI therapy implementation on patients diagnosed with heart failure. The therapy has proven to demonstrate benefits in preventing heart failure deaths. Thus, routine clinical practice using the life-saving treatment is necessary.

ARNI therapy for heart failure treatment

The Angiotensin receptor neprilysin inhibition (ARNI) therapy is an FDA-approved cardiovascular treatment. It offers survival benefit for patients diagnosed with heart failure. It is able to reduce ejection fraction in many clinical trials and it also effectively reduces death rate in heart failure when implemented optimally, Scifeeds reported.  

Heart failure in America

Heart failure is estimated to be the cause of 300,000 deaths per year. The need of effective therapy that provides benefits might postpone the deaths of 28,484 people in the United States.